



INTERIM MANAGEMENT DISCUSSION AND ANALYSIS
FOR THE THREE MONTHS AND SIX MONTHS ENDED JUNE 30, 2023.

(EXPRESSED IN CANADIAN DOLLARS)

FORWARD LOOKING STATEMENTS

This MD&A contains certain statements that may constitute “forward-looking statements”. Forward-looking statements include but are not limited to, statements regarding future anticipated business developments and the timing thereof, regulatory compliance, sufficiency of working capital, and business and financing plans. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made, and they involve several material risks and uncertainties. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: believe, expect, anticipate, intend, estimate, postulate, and similar expressions, or which by their nature refer to future events. The Company cautions investors that any forward-looking statements by the Company are not guarantees of future performance, and that actual results may differ materially from those in forward looking statements because of various factors, including, but not limited to, the Company’s ability to continue its projected growth, to raise the necessary capital or to be fully able to implement its business strategies.

The Company has based the forward-looking statements largely on the Company's current expectations, estimates, assumptions, and projections about future events and financial and other trends that the Company believes, as of the date of such statements, may affect its business, financial condition, and results of operations. Such expectations, estimates, assumptions, and projections, many of which are beyond the Company’s control, include, but are not limited to: management’s expectations regarding the future business, objectives and, operations of the Company; the Company’s anticipated cash needs and the need for additional financing; the Company’s ability to successfully complete future financings; the acceptance by the marketplace of new technologies and solutions; the Company’s expectations regarding its competitive position; the Company’s expectations regarding regulatory developments and the impact of the regulatory environment in which the Company operates; the Company’s ability to attract and retain qualified management personnel and key employees; and anticipated trends and challenges in the Company’s business and the markets in which it operates. Assumptions underlying the Company's working capital requirements are based on management's experience with other public companies.

Forward-looking statements regarding treatment by governmental authorities assumes no material change in regulations, policies, or the application of the same by such authorities. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made, and readers are advised to consider such forward-looking statements with the risks set forth.

The following Management’s Discussion and Analysis (“MD&A”) of Leveljump should be read in conjunction with the Company’s Unaudited Consolidated Financial Statements for the period ended June 30, 2023, together with notes thereto (the “Financial Statements”). The Company’s Unaudited Consolidated Financial Statements for the period ended June 30, 2023, have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”) and interpretations issued by the IFRS Interpretations Committee (“IFRIC”). All amounts herein are presented in Canadian dollars, unless otherwise noted. This Management’s Discussion and Analysis is dated August 29, 2023, and has been approved by the Board of Directors of the Company.

The Company’s Audited Consolidated Financial Statements and its Annual Information Form are available on SEDAR at www.sedar.com

OVERALL PERFORMANCE

Summary of Business

Leveljump Healthcare Corp. (“Jump” or the “Company”) is incorporated under the Ontario Business Corporations Act. The Company’s registered head office is 207-52 Scarsdale Rd., Toronto, ON, Canada M3B 2R7. The Company’s website is www.leveljumphealthcare.com.

The Company’s principal business activity is providing radiology services both by providing direct patient images and by providing Teleradiology services. Teleradiology is the process of providing remote off site reading of radiology scans such as CT, MRI, US, and X-ray. Hospital staff scan their emergency room patients, then page the Company’s radiologist on call, who can then remotely view, via secured server, the images and diagnose the patient and provide a report back to the hospital.

Results for Q2 2023

Total revenue for the second quarter was very strong at \$3,122,046. Revenue for the six months ended June 30, 2023, was \$6,000,277, a year over year increase of over 39%.

Teleradiology revenues were \$2,507,514 which was an increase of 34.5% compared to the second quarter of 2022. The demand for CTS services is strong. Hospitals are trying to open access to more imaging overnight for their ER departments, which would increase the patient scan volume that CTS reads. Client hospitals have had some issues with staffing, and as the problem is resolved, we anticipate volume to increase further.

Revenues from our IHF’s totalled \$453,170 in the second quarter of 2023 a slight increase over the second quarter of 2022. Patient visits are increasing and demands for services remains strong.

The Company did experience a tight labour pool, as is the experience with the broader healthcare market in Ontario. Efforts continue to recruit additional radiologists to ensure fluidity in coverage.

Industry Events and Trends

In Ontario, the healthcare system continues to work on resolving the backlog of patient tests, appointments, and surgeries that resulted from shutdowns during the pandemic. The tightening of the healthcare worker labour force continues to put a strain on the system. To help alleviate this problem the government of Ontario has proposed, but not yet finalized, a plan to make it easier for qualified health care workers who are licensed in other jurisdictions, the ability to work in Ontario. With a combination of hospitals backlogs and patients’ preference to stay away from hospitals unless necessary, our IHF clinics continue to see strong demand that we believe will continue throughout 2023.

The government of Ontario recently announced changes within the medical imaging field. A proposal was made to allow for additional privately run MRI and CT modalities. The details of the process on applying for a license will be released in late September. Leveljump will be applying for licenses, however there are no assurances that we will be successful.

Outlook

We continued our trend of increasing revenues for both our teleradiology services and our IHF's in the second quarter. Our hospital clients have seen increased patient visits leading to greater demand for our radiology reading, particularly for overnight service. Hospitals have been increasing CT technologist hours, which leads to the increased volumes.

Our IHF's continue to expand, increasing hours of operation, and finding strategic ways to keep up with the demand in the communities we operate in. We continue with new marketing efforts and work closely with referring physician offices to ensure we are meeting their needs.

We have started building our new flagship clinic location in Toronto, making good progress, however with a shortage of tradespeople and delays in construction materials, we now anticipate opening in late Q4.

The company is currently working on closing its previously announced acquisition of four imaging centres in Calgary, Alberta. Combined the clinics would add approximately \$4,800,000 in revenue and \$870,000 in EBTIDA to the Company.

Financing and Share Issuances

During the quarter the Company raised \$950,000 in capital. We sold 7,200,000 units consisting of 1 common share and 1 common share purchase warrant, with an exercise price of \$0.20 per share and an expiry of May 31, 2025, for proceeds of \$900,000 less broker commissions of \$63,000. Additionally, we sold 50,000 units that consisted of 50,000 Preferred Class A-1 shares and 50,000 common shares for proceeds of \$50,000 less \$3,500 in broker commissions.

During the quarter the Company also issued 62,500 common shares in exchange for the conversion of 25,000 Class A-1 Preferred Shares.

LIQUIDITY AND CAPITAL RESOURCES

As of June 30, 2023, the Company had cash and cash equivalents in the amount of \$467,264 (December 31, 2022 - \$82,959).

The Company's current assets as of June 30, 2023, excluding cash and cash equivalents were \$3,265,989 (December 31, 2022: \$3,282,856) which consisted of accounts receivable in the amount of \$1,184,103 (December 31, 2022: \$1,359,641), loans receivable in the amount of \$1,890,117 (December 2022: \$1,627,833) and prepaid expenses and deposits totalling \$191,769 (December 31, 2022: \$295,382).

Current liabilities as of June 30, 2023, were \$3,414,036 (December 31, 2022: \$2,963,730) which were comprised of accounts payables and accrued liabilities of \$2,674,381 (December 31, 2022: \$2,488,148), current portion of lease liabilities \$303,630 (December 31, 2022: \$108,303), and current portion of long-term debt \$436,025 (December 31, 2022: 367,279).

The continuing operations of the Company are dependent upon its ability to raise adequate financing and to continue its operations in the future. For the quarter ended June 30, ~~2023~~ the Company had a net loss and comprehensive loss of \$237,635 and as of June 30, 2023, an accumulated deficit of \$14,786,174. These uncertainties may cast significant doubt upon the Company's ability to continue as a going concern.

Although the Company has been successful in borrowing funds or raising equity capital in the past, there can be no assurance that the Company will have sufficient financing to meet its future capital requirements, or that additional financing will be available on terms acceptable to the Company in the future. The Company has and may continue to have capital requirements more than its currently available resources.

Liquidity Risk

Liquidity risk is the risk that the Company cannot meet a demand for cash or fund its obligations as they become due. The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities as they become due. The Company is expanding and to meet its short and longer-term working capital requirements, the Company will attempt, if necessary, to secure further financing to ensure that those obligations are properly discharged. Operationally, the Company manages its liquidity by continuously monitoring forecasted and actual gross profit, expenses, and cash flows from operations. There have been no changes to this risk exposure from 2023.

The following tables illustrate the contractual maturities of financial liabilities for June 30, 2023, and December 31, 2022:

	June 30, 2023			
	Total	Payments Due by Period		
		< 1 year	1-5 years	5+ years
Accrued Liabilities	\$ 2,674,381	\$ 2,674,381	\$ -	\$ -
Lease Liabilities	1,136,911	303,630	828,674	-
Long Term Liabilities	3,829,963	436,025	3,393,938	-
Total	\$7,636,648	\$ 3,414,036	\$4,222,612	\$ -

	December 31, 2022			
	Total	Payments Due by Period		
		< 1 year	1-5 years	5+ years
Accrued Liabilities	\$ 2,488,148	\$ 2,488,148	\$ -	\$ -
Lease Liabilities	274,338	108,303	166,035	-
Long Term Liabilities	3,761,073	367,279	3,393,794	-
Total	\$ 6,523,559	\$ 2,963,730	\$ 3,559,829	\$ -

CAPITAL RESOURCES

The Company defines capital as total shareholders' equity and long-term debt. The Company manages its capital structure, based on the funds available to the Company, to support the growth and development of its operations and bring new products to market and to ensure it continues as a going concern. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business. The Company will continue to assess new opportunities and seek to acquire an interest in growth situations if it feels there is sufficient economic potential and if it has adequate financial resources to do so.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There were no changes in the Company's approach to capital management during the quarter ended June 30, 2023 or the year ended December 31, 2022. The Company is not subject to externally imposed capital requirements other than those on its TD Long Term Debt which include priority rights against CTS, maintaining a debt to adjusted EBITDA ratio of 3.75 times as of June 30, 2023, and maintaining a debt service coverage ratio of not less than 115%

OFF-BALANCE SHEET ARRANGEMENTS

The Company does not have any Off-Balance Sheet arrangements.

RELATED PARTY TRANSACTIONS AND BALANCES

Related parties include key management being the Company's executive officers, the Board of Directors, close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions. The following related party transactions were conducted during the period ended June 30, 2023:

	Period Ended June 30, 2023	Year Ended December 31, 2022
Key management compensation	\$684,152	\$1,151,082
Share-based compensation	nil	\$293,332
	<u>\$684,152</u>	<u>\$1,444,314</u>

Both the Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO") provide their services to the Company through a third-party company Leveljump Inc. that is owned 50% by the CEO and 50% by the CFO. These services are currently billed at \$43,846 per month for each officer plus HST. Total consulting fees billed by Leveljump Inc. were \$684,152 plus HST as of June 30, 2023 (December 31, 2022 - \$723,461).

As of June 30, 2023, \$ 1,009,798 (December 31, 2022 - \$ 876,294) was loaned by the Company to Leveljump Inc., \$324,921 was loaned to the CEO (December 31, 2021 - \$324,921) and \$426,618 to the CFO (December 31, 2022 - \$426,618). These loans are partially offset by past due salaries and wages due to the CEO of \$670,969 (December 31, 2022 - \$670,969) and to the CFO of \$331,181 (December 31, 2022 - \$331,181). The past due salaries are presented in accounts payable and accrued liabilities. Most of the loans are related to a salary deferral program to allow for more advantageous tax planning by the senior management. The Company expects the deferrals and loans to be settled by the first quarter of 2024. The loans are unsecured and non-interest bearing.

SECOND QUARTER RESULTS

Quarter Ended	June 30, 2023	June 30, 2022
Total revenue	\$3,122,046	\$2,335,794
Gross margin	912,353	664,745
Operating Expenses	1,135,825	793,822
Net (loss) / income	(237,635)	(183,827)
Loss per share—basic and diluted	\$(0.00)	\$(0.00)

REVENUES

Teleradiology

For the three months ended June 30, 2023, the Company's teleradiology revenue increased by \$642,720 to \$2,507,514 compared to \$1,864,794 for the same period in 2022.

Diagnostic Imaging Services

For the three months ended June 30, 2023, the Company's Diagnostic Imaging Services revenue increased by \$31,844 to \$453,170 compared to \$421,326 for the same period in 2022. The increase is the addition of imaging modalities and staff allowing the IHF's to be open with longer hours for patients.

Admin and Other

For the three months June 30, 2023, the Company's admin and other revenue was \$161,362 which increased by \$111,688 compared to admin revenue for the same period in 2022 of \$49,674. This increase is due to the size of the Company growing through its recent acquisitions.

TOTAL REVENUE

Total revenue for the three months June 30, 2023, was up \$786,252 to \$3,122,046 compared to \$2,335,794 for the three months ended June 30, 2022.

COST OF SALES

Physician Fees

For the three months ended June 30, 2023, the Company's physician fees totalled \$1,982,112 higher by \$523,919 compared to physician fees of \$1,458,193 for the three months ended June 30, 2022. The increase in reading fees in the current three-month period is a result of the increased operations due to increased demand for the Company's services.

Technician Fees

For the three months ended June 30, 2023, the Company's technician fees totalled \$172,010 higher by \$35,609 compared to technician fees of \$136,401 for the three months ended June 30, 2022. The increase in tech fees in the current three-month period is a result of the increased operations due to increased demand for the Company's services.

Medical Imaging Software

PACS costs for the three months ended June 30, 2023, was \$48,583 compared to \$68,527 for the three-month period ended June 30, 2022. The decrease is the result of changing to a new imaging software and cost recuperation associated with the new software.

Supplies

For the three months ended June 30, 2023, the Company's supplies costs totalled \$6,988 compared to \$7,928 for the three-month period ended June 30, 2022.

TOTAL COST OF SALES

Total cost of sales during the second quarter in 2023 including physician fees, technical fees, medical imaging software, and supplies totalled \$2,209,692 compared to \$1,671,049 for the three-month period ended June 30, 2022.

GROSS PROFIT

As a result of the above revenues net of cost of sales, the Company's gross margin increased by \$247,608 to \$912,353 for the three-month period ending June 30, 2023, versus gross margin of \$664,745 for the same three-month period in 2022.

EXPENSES

Salaries and Wages

For the three months ended June 30, 2023, the Company recorded salaries and wages of \$172,237 compared to \$208,709 for the same three-month period ended June 30, 2022. The decrease in salaries recorded in the second quarter of fiscal 2023 was a result of the re-capture of an allowance for additional payroll taxes.

Advertising and Marketing

For the three months ended June 30, 2023, the Company recorded advertising and marketing expenses for \$8,359. Marketing and advertising expenses for the same period in 2022 was \$(6,887). The decrease in advertising and marketing expenses occurred in the quarter for contracts signed in 2021 for investor outreach and institutional outreach related to the Company's qualifying transaction and listing on the TSXV exchange that were continued into 2022 but not renewed for 2023.

Professional Fees

For the three months ended June 30, 2023, the Company recorded professional fees of \$656,420 up considerably by \$263,024 compared to \$393,396 for the three months ended June 30, 2022. The increase in professional fees for the three months ended June 30, 2023, was primarily attributed to increased consulting fees in the second quarter due to the CEO's contract being reclassified under consulting.

General and Administrative

General and administrative costs totalled \$109,731 up \$36,198 for the three months ended June 30, 2023, compared to general and administrative costs of \$73,533 for the same three-month period in 2022. The Company experienced an increase in general and administrative costs during the current period in fiscal 2023, because of additional expenses incurred by the IHF centres.

Insurance

Insurance expense for the three months ended June 30, 2023, decreased by \$(15) to \$23,763 when compared to \$23,778 for the same period in 2022.

Depreciation and Amortization

For the three months ended June 30, 2023, depreciation and amortization costs increased significantly by \$67,082 to \$120,118 compared to \$53,036 for the same period in 2022. This increase was due to additional amortization and depreciation on equipment and property related to the IHF centres.

Premises Rental

For the three months ended June 30, 2023, the Company's premises rental costs increased by \$33,774 to \$45,198 compared to \$11,424 for the same period in 2022. This increase reflects the opening of a new IHF center in 2023 and the rent due on the IHF centers.

TOTAL OPERATING EXPENSES

Total expenses for the three months ended June 30, 2023, were \$1,135,825, higher by \$342,003 when compared to total expenses of \$793,822 for the three months ended June 30, 2022. The primary factors relating to the increase in total expenses during the second quarter of 2023 were due the increase in professional fees expense by \$263,024, general and administrative expenses which increased by \$36,198, depreciation and amortization expenses which increased by \$67,082, premises rental which increased by 33,774 and advertising and marketing expenses which increased by \$15,246.

OTHER INCOME

For the three months ended June 30, 2023, other income was \$114,096, whereas in 2022 for the same period it was \$400. The other income is related to gains from the sale of the Company's interest in the Shaw companies.

OTHER EXPENSES

Finance Costs

For the three months ended June 30, 2023, the Company recorded finance costs of \$61,461 which increased significantly by \$25,242 versus finance costs of \$36,219 for the three-month period ended June 30, 2022. The increase in finance costs during the first quarter of 2023 was primarily related to increased interest on the TD Loans due to the increased borrowing related to the purchase of new IHF license and equipment.

Broker Commissions

For the three months ended June 30, 2023, the Company broker commission increased by \$46,299 to \$66,500 compared to \$20,201 for the same period in 2022. The increase relates to broker commission costs from private placement financing.

Reconciliation Discrepancies

For the three months ended June 30, 2023, the Company reconciliation discrepancies was \$(13) whereas in the same period in 2022 it was \$(1,270). These costs were directly related to reconciliation discrepancies which the company faced as a direct result of migrating between two accounting systems.

Foreign Exchange Loss

For the three months ended June 30, 2023, the foreign exchange loss was recorded at \$313. In the second quarter of 2022 foreign exchange loss was \$nil.

TOTAL EXPENSES

Total expenses for the three months ended June 30, 2023, were \$1,264,085, increased by \$415,113 compared to \$848,972 for the three-month period ended June 30, 2022. The increase in total expenses for the three-month period ended June 30, 2023, was primarily related to professional fees, general and administrative, salaries and wages, depreciation and amortization, premises rental, advertising and marketing expenses, financial costs, and broker commissions.

NET LOSS AND COMPREHENSIVE LOSS

As a result of the above factors, the net loss and comprehensive loss for the three months ended June 30, 2023, was \$237,635 compared to a net income and comprehensive loss of \$183,827 for the three months ended June 30, 2022.

SIX MONTH RESULTS

Period Ended	June 30, 2023	June 30, 2022
Total revenue	\$6,000,277	\$4,321,208
Gross margin	1,757,511	1,153,243
Operating Expenses	2,125,973	1,685,988
Net (loss) / income	(445,603)	(527,073)
Loss per share—basic and diluted	\$(0.01)	\$(0.01)

REVENUES

Teleradiology

For the 6 months ended June 30, 2023, the Company's teleradiology revenue increased by \$1,254,584 to \$4,812,447 compared to \$3,557,863 in 2022.

Diagnostic Imaging Services

For the six months ended June 30, 2023, the Company's Diagnostic Imaging Services revenue increased by \$208,234 to \$885,605 compared to \$677,371 in 2022.

Admin and Other

For the six months June 30, 2023, the Company's admin and other revenue was \$302,225 which increased by \$216,251 compared to admin revenue for the same period in 2022 of \$85,974.

TOTAL REVENUE

Total revenue for the six months June 30, 2023, was up \$1,679,069 to \$6,000,277 compared to \$4,321,208 for the six months ended June 30, 2022. The increase in total revenue is primarily a result of the increased teleradiology revenue and the revenue produced from the acquisition of the IFH centres.

COST OF SALES

Physician Fees

For the six months ended June 30, 2023, the Company's physician fees totalled \$3,772,609 higher by \$992,750 compared to physician fees of \$2,779,859 for the six months ended June 30, 2022. The increase in reading fees in the current six-month period is a result of the increased operations due to increased demand for the Company's services.

Technician Fees

For the six months ended June 30, 2023, the Company's technician fees totalled \$361,576 increased by \$116,502 compared to the technician fees of \$245,074 for the same period in 2022. The increase in technician fees in the current six-month period is a result of the increased operations due to increased demand for the Company's services.

Medical Imaging Software

PACS costs for the six months ended June 30, 2023, was \$92,573 compared to \$129,718 for the six-month period ended June 30, 2022.

Supplies

For the six months ended June 30, 2023, the Company's supplies costs totalled \$16,009 compared to \$13,314 in the same period in 2022.

TOTAL COST OF SALES

Total cost of sales during the first half of 2023 including physician fees, technician fees, medical imaging software, and supplies expenses were \$4,242,767 compared to \$3,167,965 during the same period in 2022. Higher cost of sales experienced during the first half of 2023 was primarily a result of costs associated with the IHF acquisition in addition to increased operations due to higher demand for the Company's services.

GROSS PROFIT

As a result of the above revenues net of cost of sales, the Company's gross margin increased by \$604,268 to \$1,757,511 for the six-month period ending June 30, 2023, versus gross margin of \$1,153,243 for the same six-month period in 2022.

EXPENSES

Professional Fees

For the six months ended June 30, 2023, the Company recorded professional fees of \$1,209,009 up considerably by \$509,365 compared to \$699,644 for the six months ended June 30, 2022. The increase in

professional fees for the six months ended June 30, 2023, was primarily attributed to increased consulting fees in the second quarter due to revisions in management compensation contracts.

Salaries and Wages

For the six months ended June 30, 2023, the Company recorded salaries and wages of \$373,908 compared to \$452,427 for the same three-month period ended June 30, 2022. The decrease in salaries recorded in the second half of fiscal 2023 was a result of the re-capture of an allowance for additional payroll taxes.

General and Administrative

General and administrative costs totalled \$194,932 up \$61,410 for the six months ended June 30, 2023, compared to general and administrative costs of \$133,522 for the same six-month period in 2022. The Company experienced an increase in general and administrative costs during the current period in fiscal 2023, because of additional expenses incurred by the IHF centres.

Depreciation and Amortization

For the six months ended June 30, 2023, depreciation and amortization costs increased significantly by \$118,160 to \$212,193 compared to \$94,033 for the same period in 2022. This increase was due to additional amortization and depreciation on equipment and property related to the IHF centres.

Insurance

Insurance expense for the six months ended June 30, 2023, increased by \$1,050 to \$48,006 when compared to \$46,956 for the same period in 2022.

Premises Rental

For the six months ended June 30, 2023, the Company's premises rental costs increased by \$44,112 to \$67,450 compared to \$23,338 for the same period in 2022. This increase reflects the new IHF centre & rent due on the IHF centres.

Advertising and Marketing

For the six months ended June 30, 2023, the Company recorded advertising and marketing expenses for \$20,473 increased by \$4,071 whereas in the same period 2022 it was \$16,402.

TOTAL OPERATING EXPENSES

Total expenses for the six months ended June 30, 2023, were \$2,125,973, higher by \$439,985 when compared to total expenses of \$1,685,988 for the six months ended June 30, 2022. The primary factors relating to the increase in total expenses during the second quarter of 2023 were due the increase in professional fees by \$509,365, general and administrative by \$61,410, depreciation and amortization by \$118,160, insurance by \$1,050, premises rental by \$44,112 and advertising and marketing by \$4,071.

OTHER INCOME

For the six months ended June 30, 2023, other income was \$116,604, whereas in 2022 for the same period it was \$92,769. The other income in 2023 is related to gains from the sale of the Company's interest in the Shaw companies. The increase in other income for the first half of 2022 is related to recapture of allowance for payroll taxes.

OTHER EXPENSES

Finance Costs

For the six months ended June 30, 2023, the Company recorded finance costs of \$117,174 which increased significantly by \$57,093 versus finance costs of \$60,081 for the six-month period ended June 30, 2022. The increase in finance costs during the first half of 2023 was primarily related to interest on the TD Loan.

Broker Commissions

For the six months ended June 30, 2023, the Company recorded broker commission costs of \$66,500 versus in the same period in 2022 it was \$20,201 increased by \$46,299.

Reconciliation Discrepancies

For the six months ended June 30, 2023, the Company reconciliation discrepancies was \$164 whereas in the same period June 30, 2022, it was \$2,289, lower by \$2,125. These costs were directly related to reconciliation discrepancies which the company faced as a direct result of migrating between two accounting systems.

Other Miscellaneous Expenses

For the six months ended June 30, 2023, the Company recorded \$310 for miscellaneous expenses, compared to \$(100) that was recorded for the same period in 2022. The miscellaneous expenses recorded in 2023 were related to an accounts payable write-off that were no longer due.

Foreign Exchange Loss

Foreign exchange loss of \$396 was recorded in the first half of 2023 compared to \$4,626 for the same period in 2022.

Other Income Tax

For the six months ended June 30, 2023, the Company other income tax was \$9,202. There was no comparable amount for the same period in 2022.

TOTAL OTHER EXPENSES

Total expenses for the six months ended June 30, 2023, were \$193,746, increased by \$106,649 compared to \$87,097 for the six-month period ended June 30, 2022. The increase in total expenses for the six-month period ended June 30, 2023, was primarily related to financial costs, reconciliation discrepancies and income tax.

NET LOSS AND COMPREHENSIVE LOSS

As a result of the above factors, the net loss and comprehensive loss for the six months ended June 30, 2023, was \$445,603 compared to a net loss and comprehensive loss of \$527,073 for the six months ended June 30, 2022, an increase of \$81,470.

LOSS PER SHARE – BASIC AND DILUTED

The loss per share-basic and diluted for the six months ended June 30, 2023, was \$0.01 same as the loss per share-basic and diluted of \$0.01 for the comparable six-month period in 2022.

PROPOSED TRANSACTIONS

The company is currently working on closing its previously announced acquisition of four imaging centres in Calgary, Alberta. Combined the clinics would add approximately \$4,800,000 in revenue and \$870,000 in EBTIDA to the Company.

The Company does not have any other proposed transactions.

CHANGES IN ACCOUNTING POLICIES

The Company adopted an equipment depreciation schedule for its newly acquired medical equipment and leasehold improvements which includes a straight-line method and a useful life of 10 years. There were no other accounting policy changes in the year, and none are planned for the of 2023.

FINANCIAL INSTRUMENTS AND OTHER INSTRUMENTS

During 2022 the Company's subsidiary, CTS, borrowed \$3,200,000 from TD Canada Trust in 5 loan agreements. The first was for \$3,200,000 amortized over 10 years with a 5-year term and an interest rate locked in for a 2-year term at a rate of 4.02%. The second loan was for \$700,000 at a rate of 6.66% for a term of 2 years and blended with the first loan for amortization. The third loan was for up to \$600,000 for the purchase of equipment and leasehold improvements. Approximately \$85,392 of the third loan has been advanced as of December 31, 2022, at a rate of 6.28% with a 5-year term. Fourth loan has been advanced around \$139,735.87 as of January 01, 2023, at a rate of 6.55% with a 5-year term. Lastly, approximately \$172,000 of the fifth loan has been advanced as of January 01, 2023, at a rate of 6.48%.

Credit risk

Credit risk is the risk of loss associated with a counter-party's inability to fulfill its payment obligations. The Company's cash and accounts receivable are exposed to credit risk. Jump's cash is held with a major Canadian-based financial institution and as such management believes that the associated credit risk is remote.

Account receivables represents revenue earned from services rendered to hospitals. The Company has adopted a credit policy under which each new customer is analyzed individually for creditworthiness before the Company's standard payment terms and conditions are offered.

The Company's trade receivables are concentrated among customers in the healthcare industry, which may be affected by adverse government policy impacting that industry. As of June 30, 2023, three customers accounted for greater than 63% of the Company's trade receivable balance.

There have been no changes to this risk exposure from 2023.

The Company's maximum exposure to credit risk as of June 30, 2023, and December 31, 2022, was as follows:

	June 30, 2023	December 31, 2022
Cash and Cash Equivalents	\$ 467,264	\$ 82,959
Accounts Receivable	1,184,103	1,359,641
Loans Receivable	1,890,117	1,627,833
Prepaid Expenses and Deposits	191,769	295,382
Total	\$ 3,733,253	\$ 3,365,815

SHARE CAPITAL AND RESERVES

Authorized Share Capital

Common Shares

As at the date of filing this report the Company had 94,469,729 common shares outstanding. (see Note 12 in Financial Statements)

Preferred Shares

As of the date of filing this report the Company had 139,000 Class A-1 Preferred Shares outstanding (see Note 12 in Financial Statements).

Stock Options

As at the date of filing this report the Company had 8,287,668 options issued and outstanding, of which all except for 800,000 are vested and exercisable into shares of common stock. (Financial Statements Note 13)

Warrants

As at the date of filing this report the Company had 48,060,261 common share purchase warrants issued and outstanding. (Financial Statements Note 14)

Broker Options

As at the date of filing this report the Company had 696,040 broker options issued and outstanding, each convertible into a unit consisting of 1 common share and 1 common share purchase warrant. (Financial Statements Note 15)